Poly ADP ribose polymerase (PARP) for the treatment of BRCA-mutated advanced ovarian cancer

被引：0
|
作者：
Yunokawa, Mayu [1 ]
机构：
[1] JFCR, Canc Inst Hosp, Gynecol Oncol & Med Oncol Dept, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz336.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MS3 - 4
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [31] Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
    Papa, Anselmo
    Caruso, Davide
    Strudel, Martina
    Tomao, Silverio
    Tomao, Federica
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [32] Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019
    Vetter, Monica Hagan
    Smrz, Stacy A.
    Copeland, Larry J.
    Cohn, David E.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 223 (03) : 469 - 470
  • [33] Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
    Anselmo Papa
    Davide Caruso
    Martina Strudel
    Silverio Tomao
    Federica Tomao
    Journal of Translational Medicine, 14
  • [34] Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer
    Onstad, Michaela
    Coleman, Robert L.
    Westin, Shannon N.
    DRUGS, 2020, 80 (15) : 1525 - 1535
  • [35] Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer
    Michaela Onstad
    Robert L. Coleman
    Shannon N. Westin
    Drugs, 2020, 80 : 1525 - 1535
  • [36] Exploration of poly (ADP-ribose) polymerase inhibitor resistance in the treatment of BRCA1/2-mutated cancer
    Wu, Shuyi
    Yao, Xuanjie
    Sun, Weiwei
    Jiang, Kaitao
    Hao, Jie
    GENES CHROMOSOMES & CANCER, 2024, 63 (05):
  • [37] Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis
    Wang, Ju
    Zhang, Ye
    Yuan, Long
    Ren, Lin
    Zhang, Yi
    Qi, Xiaowei
    AGING-US, 2021, 13 (01): : 450 - 459
  • [38] PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis
    Yan, Feifei
    Jiang, Qi
    He, Mengye
    Shen, Peng
    FUTURE ONCOLOGY, 2021, 17 (18) : 2381 - 2393
  • [39] Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors
    Gupta, Shruti
    Hanna, Paul E.
    Ouyang, Tianqi
    Yamada, Karla Sofia
    Sawtell, Rani
    Wang, Qiyu
    Katz-Agranov, Nurit
    Feghali, Lea
    Krasner, Carolyn N.
    Bouberhan, Sara
    Castro, Cesar M.
    Sise, Meghan E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (07): : 831 - 837
  • [40] Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios, Stergios
    Moschetta, Michele
    Karihtala, Peeter
    Samartzis, Eleftherios P.
    Sheriff, Matin
    Pappas-Gogos, George
    Ozturk, Mehmet Akif
    Uccello, Mario
    Karathanasi, Afroditi
    Tringos, Michail
    Rassy, Elie
    Pavlidis, Nicholas
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
12345